Better Health for All

Boundless Bio's entire business is devoted to developing ecDNA-directed therapies for oncogene amplified cancers, which represent a significant unmet medical need affecting over 14% of cancer patients with poor outcomes.

This focus positions 95-97% of its portfolio to deliver exceptional health benefits if successful. However, the company's BBI-355 program demonstrated a narrow therapeutic index with hematological toxicity at certain doses in the POTENTIATE trial, and combination therapies also had poor tolerability, indicating few safety incidents but with notable severity. The company disclosed these safety concerns and the rationale for discontinuing certain arms of the POTENTIATE trial, demonstrating comprehensive risk disclosures. Additionally, the company announced a workforce reduction of approximately one-third, indicating substantial support for the healthcare workforce is not being maintained.

Fair Money & Economic Opportunity

Boundless Bio, Inc. is a clinical-stage oncology company focused on developing cancer therapeutics.

Its core business does not involve lending, insurance, moving, or storing money, nor does it offer consumer financial products or services. Therefore, the Key Performance Indicators related to fair money and economic opportunity, which are designed for financial institutions, are not applicable to Boundless Bio's operations.

Fair Pay & Worker Respect

As of March 21, 2025, Boundless Bio had 64 full-time employees, indicating that 100% of its workforce was on secure contracts.

The company reported no employees represented by labor unions or covered by collective bargaining agreements. There were no specific regulatory actions, violations, or fines mentioned in the provided articles. The company also stated that 'Mine Safety Disclosures' were not applicable, suggesting an absence of hazardous operations.

Fair Trade & Ethical Sourcing

The provided articles, including the company's S-1 registration statement, explicitly state that no quantitative data or specific information is available regarding fair trade certifications, supplier audit frequency, forced or child labor incidents, supply chain traceability, remediation speed for violations, ethical clause coverage in supplier contracts, materials risk index, or supplier diversity spend.

Therefore, no assessment can be made against the Fair Trade & Ethical Sourcing value for any KPI.

Honest & Fair Business

No specific, quantitative, or concrete evidence was found across the provided articles to assess Boundless Bio, Inc. against any of the 'Honest & Fair Business' KPIs. The articles mention general corporate information

, board committee composition , and corporate governance documents like codes of conduct , but lack the specific data points required for scoring, such as regulatory fines, transparency index scores, details on whistleblower policy strength, financial restatement numbers, audit coverage percentages, ESG controversy scores, complaint resolution times, board conflict of interest percentages, anti-corruption policy specifics, or third-party verification extent.

Kind to Animals

No specific, concrete data points were found in the provided articles for Boundless Bio, Inc. (BOLD.US) regarding any of the 'Kind to Animals' KPIs. While one article mentions the company conducts 'preclinical research on a new cancer drug... focuses entirely on cancer research in mice,' this fact alone does not provide the quantitative data (e.g., number of animals, percentage of products, investment figures) or policy details required to score any of the defined KPIs.

The articles explicitly state that animal welfare metrics, quantitative data on animal testing, humane certifications, or alternative testing methods are not provided for BOLD.US.

No War, No Weapons

Boundless Bio, Inc. is a clinical-stage oncology company with no revenue from product sales to date.

Its R&D is exclusively focused on developing therapeutics for cancer. The company's core business has no defense or arms-related activities, and therefore no exposure to controversial weapons, conflict minerals, or procurement from conflict zones. The company has a Code of Business Conduct and Ethics and an ethics hotline for reporting violations, but no specific ethical red lines related to weapons are mentioned, as they are not applicable to its business model.

Planet-Friendly Business

The provided articles do not contain any specific, concrete data points for Boundless Bio, Inc. (BOLD.US) regarding its own environmental performance, targets, or initiatives.

While some articles mention 'Boundless Impact Research & Analytics' or 'Boundless Impact' as a provider of environmental analysis and life cycle assessment services, this information pertains to a service provider (likely a separate entity given the different website domains and business descriptions) and not to Boundless Bio, Inc.'s own operations or products. Therefore, no KPIs can be scored based on the evidence provided for BOLD.US.

Zero Waste & Sustainable Products

Boundless Bio, Inc. is committed to managing its assets in a manner protective of human health, safety, and the environment, and requires compliance with laws covering environmental hazards.

The company and its suppliers use potent chemical agents and hazardous materials and are subject to laws regarding their use, storage, and disposal. The company's lease agreement for lab and office space includes clauses requiring compliance with environmental regulations concerning hazardous materials and a decommissioning and hazardous materials closure plan. No waste disposal violations or citations were reported in the provided articles for the past three years.